

Eli Lilly and Co / LLY

Equity | Generated Aug 28, 2026 12:25 AM EDT

Current price	Daily move	Bid / Ask	Previous close
\$1,175.75	-0.35 -0.03%	\$1,177.00/\$1,179.00	\$1,176.10

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Aug 28, 2026 12:25 AM EDT

JW Intelligence Report

Complete | 3 of 3 sections | Aug 27, 2026 7:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
64.5 / 100	Balanced	high	26 / 100

Model reference	Upside scenario	Risk reference	Wheel strategy fit
\$1,175.00	\$1,245.00	\$1,140.00	70 / 100

Options stance	bullish
Tail-risk safety	56 / 100
JW Rank data coverage / as of	100.0% Aug 27, 2026 7:50 PM EDT

Key insight

LLY Option Market Implies Continued Growth Potential Despite Recent Pullback

Market read

The US option market for LLY suggests a cautiously bullish outlook despite recent price weakness. While the stock has pulled back from its 52-week high, implied volatility remains elevated, indicating anticipation of continued volatility and potential upside. The term structure is in backwardation, with near-term options more expensive than longer-dated ones, suggesting market participants expect a move higher in the near future. The skew is balanced, implying neutral sentiment towards both bullish and bearish moves.

Strategy context

Recent news flow has been mixed, with positive developments in LLY's pipeline offset by concerns about competition and valuation. This uncertainty is reflected in the elevated implied volatility and choppy price action.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias

Bullish

AI analysis updated

Aug 27, 2026 1:43 PM EDT

Short-term scenario

Cautious Buy on support amid pullback (1-3 week horizon); high uncertainty from mixed technicals, recent volatility, and news flow (competitor developments, coverage). Not a high-conviction short-term trade.

Three-month outlook

Moderately bullish but with significant uncertainty. GLP-1 franchise (Mounjaro, Zepbound, oral Foundayo) and pipeline (retatrutide BLA 2027, oncology, Alzheimer's) support continued growth and analyst targets implying ~11-15%+ upside. Next earnings ~Oct 29 2026 is a catalyst. Risks include intense competition, reimbursement/pricing pressure (Medicare, employers dropping coverage), manufacturing bottlenecks, black-market issues, high valuation leaving little margin for error, and broader market volatility. Expect chopiness; longer-term thesis intact if execution holds, but 3-month path highly uncertain depending on data, policy, and competitor moves.

Market sentiment

Cautiously bullish overall with valuation caveats. Bulls emphasize GLP-1 market dominance, 48% growth, retatrutide pipeline, Alzheimer's progress, and long-term compounding (some Elliott Wave targets \$1,571-\$1,755). Recent options flow noted bullish calls. Bears/skeptics highlight premium valuation (PE~40), competition (Novo Nordisk weakness helping relatively), manufacturing risks, potential price caps/reimbursement issues, black market, and high institutional ownership. Mixed on recent dip (bounce setups vs. overbought concerns earlier). Sentiment positive on fundamentals but acknowledges execution/valuation risks; not uniformly euphoric.

Supporting evidence


Implied volatility for LLY is currently 30.9%, indicating expectations of significant price movement in the coming weeks. | The term structure of options is in backwardation, with near-term options more expensive than longer-dated ones, suggesting a belief that the stock will move higher soon. | The balanced skew indicates neutral sentiment towards both bullish and bearish moves.

Risk watch

Competition from other GLP-1 manufacturers could pressure LLY's market share and growth prospects.

Enhanced price structure


45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

bullish_recovery

Institutional flow

Below MVWAP

Structure

Above 200D trend

Volatility

medium

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	BULLISH RECOVERY neutral MACD decelerating
Trend signal	BULLISH RECOVERY
RSI signal	neutral
RSI (7 / 14 / 21)	36.73 / 45.69 / 48.84
RSI velocity	-4.04
MACD line / signal / histogram	11.34 / - / 15.54
MACD acceleration	-3.34
Stochastic K / D	28.78 / 48.69

Institutional footprints

Volume-weighted cost, price location and flow

Current read	Below institutional MVWAP Accumulation bias
Institutional flow	0.59
20-day MVWAP	\$1,197.87
Price vs 20-day MVWAP	-1.85%
Daily reference VWAP	\$1,179.31
Price vs daily reference	-0.30%
Volume	1.19M

Structural context

Long-term trend and volatility boundaries

Current read	Above 200-day trend Positive macro velocity
Macro velocity	0.23
20-day / 200-day SMA	\$1,201.25 / \$1,058.74
Bollinger range	\$1,114.61 - \$1,287.88
Bollinger position	0.355

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank

23 / 100

IV percentile

20 / 100

VVIX

83.51

SKEW

142.96

Market regime	Calm
Tail-risk regime	NORMAL TAIL RISK
Term structure	backwardation
Term slope	-8.05 pts
Skew read	balanced
Liquidity / quote coverage	100.0%
Options observation	Aug 27, 2026 4:33 PM EDT Coverage 88.9%

Option term structure


ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-08-28	1	37.8%	-
2026-09-04	8	31.2%	-
2026-09-11	15	29.7%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit



Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	2026-10-29
Earnings IV-crush risk	NOT MEASURED
VIX	14.74
VVIX	83.51
SKEW index	142.96
Observation confidence	high
Option quote quality	reliable
Contracts observed	131
Contracts with quotes	131

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The US option market for LLY suggests a cautiously bullish outlook despite recent price weakness. While the stock has pulled back from its 52-week high, implied volatility remains elevated, indicating anticipation of continued volatility and potential upside. The term structure is in backwardation, with near-term options more expensive than longer-dated ones, suggesting market participants expect a move higher in the near future. The skew is balanced, implying neutral sentiment towards both bullish and bearish moves.

Options context

LLY Option Market Implies Continued Growth Potential Despite Recent Pullback

Wheel context

Recent news flow has been mixed, with positive developments in LLY's pipeline offset by concerns about competition and valuation. This uncertainty is reflected in the elevated implied volatility and choppy price action.

Observed evidence

Implied volatility for LLY is currently 30.9%, indicating expectations of significant price movement in the coming weeks. | The term structure of options is in backwardation, with near-term options more expensive than longer-dated ones, suggesting a belief that the stock will move higher soon. | The balanced skew indicates neutral sentiment towards both bullish and bearish moves.

Principal risks to monitor

Competition from other GLP-1 manufacturers could pressure LLY's market share and growth prospects.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
\$1.11T	43.17
ROE	Revenue growth
92.6%	31.7%
EPS growth	Operating margin
49.3%	42.2%
Net profit margin	Gross margin
33.5%	-
Free cash flow CAGR	Debt / equity
5.9%	1.60
Dividend yield	Beta
0.8%	0.45
52-week range	
\$712.05 - \$1,292.65	

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Co	NYSE
Industry	Country
Pharmaceuticals	US
Currency	IPO date
USD	1970-07-09
Shares outstanding	52-week return
941.74M	61.6%
Book value per share	Revenue per share
\$35.98	\$89.14
Website	lilly.com



Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal Covered Call 2026-09-04 At signal \$1,184.15 Current \$1,175.75 SHORT Option \$1,180.00 B \$24.60 / A \$28.05 High turnover CR \$26.33	Aug 27, 2026 10:34 AM EDT
---	---------------------------

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	\$40.11
ATR as % of price	3.4%
Volatility environment	medium
Current IV	32.0%
IV rank	28 / 100
IV percentile	26 / 100

Technical health and risk radar

Derived indicator health and event context

Overall health	77 / 100
Trend health	78 / 100
Momentum health	83 / 100
Volatility health	59 / 100
Structure health	85 / 100
Earnings risk / date	low 2026-10-29
Macro risk	unknown
Volatility risk	medium
Structure risk	low

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	\$1,201.25 / \$1,185.59 / \$1,058.74
EMA (9 / 21)	\$1,214.06 / \$1,206.80
Bollinger upper / middle / lower	\$1,287.88 / \$1,201.25 / \$1,114.61
Bollinger %B	0.355
True high / low	\$1,190.11 / \$1,171.71

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
5-day true high / low	\$1,271.22 / \$1,171.71

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	0.225	-
SMA50	1.429	-
MVWAP20	0.591	-
MACD	-3.337	-
RSI	-4.045	-
Volume	133377.670	-
ATR	-0.345	-
T1	-	16.06 / 1196.77 / 1235.78 / 1180.01
T2	-	20.49 / 1197.11 / 1264.73 / 1229.79
T3	-	21.35 / 1196.10 / 1262.14 / 1230.95

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	\$1,182.92
Options intelligence as of	Aug 27, 2026 4:33 PM EDT
Options data coverage	88.9%
SKEW regime	HIGH TAIL RISK SKEW
VVIX regime	VVIX FLAT
Front expiration / DTE	2026-08-28 1 DTE
Front at-the-money IV	37.8%
25-delta skew	0.77
Put / Call 25-delta	\$1,165.00 Delta -0.238 / \$1,200.00 Delta 0.232
Median option bid/ask spread	34.8%
Bid/ask spread	-
Contracts observed / quoted	131 / 131

Price context

Last Price: 1,182.92 | Bid: 1,181.50 | Ask: 1,182.45 | Previous Close: 1,189.41 | Change: -6.49 |
 Daily change: -0.55% | Update Time: 2026-08-27T14:44:15.904539-04:00 | Latest History Date: 2026-08-27
 | Latest History Price: 1,182.92

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-03 | Latest Date: 2026-08-27 | Latest Price:
 1,182.92 | Max Drawdown 60d Percent: -9.70%

Fundamental context

Current Iv Percent: 30.90% | Iv Rank: 22.55 | Iv Percentile: 20.32 | Next Earnings Date: 2026-10-29 |
 Ex Dividend Date: 2026-08-13 | Dividend Yield: 58.00

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Aug 28, 2026 12:25 AM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	jasonwheel.com
Terms of Use	jasonwheel.com / Terms
Privacy Policy	jasonwheel.com / Privacy
Options Disclosure Document	theocc.com / Options Disclosure Document